Dr. Kirson Discusses the LUNAR Study in Advanced NSCLC

Eilon Kirson, MD, PhD
Published: Thursday, May 10, 2018



Eilon Kirson, MD, PhD, chief medical officer, Novocure, discusses the LUNAR study in advanced non–small cell lung cancer (NSCLC).

LUNAR is a phase III study in patients with stage IV NSCLC previously treated with platinum-based therapy. Investigators hypothesize that the addition of Tumor Treating Fields (TTFields) to an immune checkpoint inhibitor or docetaxel following platinum doublet failure will increase the overall survival (OS) of patients with stage IV NSCLC. Preclinical evidence has shown TTFields to be efficacious in NSCLC, and a phase I/II pilot study with pemetrexed showed the modality to be safe, Kirson says. TTFields are a localized, non-invasive, anti-mitotic treatment modality that disrupts the formation of the mitotic spindle.

Over 500 patients will be randomized 1:1 to receive TTFields with standard of care versus standard of care alone. Kirson says that due to the rapidly evolving nature of the NSCLC treatment landscape, the standard of care is open to PD-1 inhibitors, PD-L1 inhibitors, or docetaxel. The patients will be stratified based on the standard of care that they are given. The study is powered to show an OS advantage and a hazard ratio of 0.75.


Eilon Kirson, MD, PhD, chief medical officer, Novocure, discusses the LUNAR study in advanced non–small cell lung cancer (NSCLC).

LUNAR is a phase III study in patients with stage IV NSCLC previously treated with platinum-based therapy. Investigators hypothesize that the addition of Tumor Treating Fields (TTFields) to an immune checkpoint inhibitor or docetaxel following platinum doublet failure will increase the overall survival (OS) of patients with stage IV NSCLC. Preclinical evidence has shown TTFields to be efficacious in NSCLC, and a phase I/II pilot study with pemetrexed showed the modality to be safe, Kirson says. TTFields are a localized, non-invasive, anti-mitotic treatment modality that disrupts the formation of the mitotic spindle.

Over 500 patients will be randomized 1:1 to receive TTFields with standard of care versus standard of care alone. Kirson says that due to the rapidly evolving nature of the NSCLC treatment landscape, the standard of care is open to PD-1 inhibitors, PD-L1 inhibitors, or docetaxel. The patients will be stratified based on the standard of care that they are given. The study is powered to show an OS advantage and a hazard ratio of 0.75.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication
x